Cosette Pharmaceuticals, a US-based, speciality pharmaceutical company, completed the acquisition of Vyleesi, a treatment drug, from Palatin Technologies, biopharmaceutical company, for $171m. "The divestiture of Vyleesi is consistent with our strategic decision to concentrate on our robust development and clinical pipeline," Carl Spana, Palatin President and Chief Executive Officer.